

INFLUENZA VACCINES FOR THE WORLD

19-21 April 2017, CHUV/University of Lausanne, Lausanne, Switzerland

SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR IVW 2017

Influenza Vaccines for the World – IVW 2017 is the sixth international conference and exhibition in this important series of influenza vaccine meetings. The IVW conference series focuses on 'Influenza Vaccination Issues'.

The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants/delivery/vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines/technologies and their availability/delivery/implementation worldwide.

The IVW 2017 Scientific Advisory Panel invites the influenza community worldwide to submit abstracts for consideration for inclusion in the IVW 2017 oral & poster scientific programmes.

SCIENTIFIC ADVISORY PANEL

Othmar Engelhardt (NIBSC/HPA, Potters Bar, UK)

Rosalind Hollingsworth (Sanofi Pasteur, Swiftwater, Pennsylvania, USA)

John Oxford (Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

Albert Osterhaus (University of Veterinary Medicine Hannover, Hannover, Germany)

Ted Ross (University of Georgia, Athens, Georgia, USA)

Yoshihiro Kawaoka (University of Wisconsin, Madison, Wisconsin, USA)

Helen Bright (MedImmune, Liverpool, UK)

Jonathan Van Tam (University of Nottingham, UK)

Rob Lambkin-Williams (hVIVO Ltd., London, UK)

Dirk Poelaert (GSK Vaccines, Wavre, Belgium)

Ronald Kompier (FluConsult, Noordwijk, The Netherlands)

Keiji Fukuda (WHO, Geneva, Switzerland)

Manon Cox (Protein Sciences Corporation, Meriden, Connecticut, USA)

Emanuele Montomoli (VisMederi Srl, Siena, Italy)

Yotam Levin (NanoPass Technologies Ltd, Rehovot, Israel)

Manmohan Singh (Takeda Vaccines, Morrisville, North Carolina, USA)

Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)

Edward Remarque (BPRC, Rijswijk, The Netherlands)

Myra Widjoatmodjo (Janssen Vaccines, Leiden, The Netherlands)

Sean Tucker (VAXART Inc, South San Francisco, California, USA)

Nathalie Charland (Medicago, Quebec, Canada)

Kathy L. Rowlen (InDevR Inc, Boulder, Colorado, USA)

CONFERENCE SCOPE

IVW 2017 will address the following important topics:

Surveillance Issues / Burden of Disease · Immunological Issues · Social / Political / Financial Issues Surrounding Influenza Vaccination
 Novel Developments · Production / Formulation Issues / Manufacturing Issues · Vaccine Usage / Targeting Strategies
 Influenza Vaccines / Adjuvants – Improvement Issues · Pandemic Preparedness Issues / Licensing Issues



The scientific programme will include keynote lectures, contributed papers, workshops, panel discussions, satellite symposia and poster presentations emphasising all aspects of 'Influenza Vaccines' and their usage and effectiveness. Potential authors are invited to submit abstracts on any of the above topics for consideration for inclusion within the conference program.

SPECIAL SESSIONS

Universal Influenza Vaccines – Latest Developments

Innate and Acquired Immunity to Plant-Made Influenza VLP Vaccines in Adults & Elderly

IVW 2017 Workshop: Alternative Potency Assay Development for Influenza Vaccines



07.30am

Arrival & Registration & Posters Set-Up

09.30am

SESSION 1: OPENING PLENARY SESSION

Moderator: John Oxford (*Queen Mary College, University of London, London, UK*)

'The Global Action Plan (GAP) for influenza vaccines 10 years on'

Erin Sparrow, Martin Friede and Claudia Nannei (*WHO, Geneva, Switzerland*)

'Treating the host response to emerging virus diseases: Lessons learned from influenza and ebola, and implications for global health and security'

David Fedson (*Independent Consultant, Sergy Haut, France*)

'The challenge of vaccinating healthcare workers against influenza'

Jonathan Van Tam (*University of Nottingham, Nottingham, UK*)

Coffee Break & Posters Set-Up

SESSION 2: PLENARY II

Moderator: Helen Bright (*MedImmune Ltd, Liverpool, Merseyside, UK*)

'Influenza infection in quarantined volunteers for basic studies of a new generation of vaccines and antibody therapies'

John Oxford (*Queen Mary College, University of London, London, UK*)

'The past and future of LAIV'

Timo Vesikari (*University of Tampere, Tampere, Finland*)

'Beyond hemagglutinin for flu vaccines: A new analytical platform for tracking HA, NA, M1 and NP'

Kathy Rowlen (*InDevR Inc., Boulder, Colorado, USA*)

Lunch Break & Posters

SESSION 3: INFLUENZA VIRUSES

Moderator: Ted Ross (*University of Georgia, Athens, Georgia, USA*)

'Global circulation patterns of seasonal influenza viruses vary with antigenic drift'

Derek Smith (*University of Cambridge, Cambridge, UK*)

'Improvement of influenza candidate vaccine viruses'

Othmar G. Engelhardt (*NIBSC, South Mimms, Potters Bar, Hertfordshire, UK*)

'Human virus challenge models, from one century to the next: What have we learned?'

Rob Lambkin-Williams (*hVIVO Ltd, London, UK*)

'Ferret models to study vaccine strategies against influenza'

Koert Stittelaar¹, Leon de Waal¹, Geert van Amerongen¹, Marie Pohl¹, Edwin Veldhuis Kroeze¹ and Albert Osterhaus^{1,2,3}

(¹ *Viroclinics Biosciences B.V., Rotterdam, The Netherlands*; ² *Artemis One Health, Utrecht, The Netherlands*; ³ *University of Veterinary Medicine, Hannover, Germany*)

'COBRA HA induced hemagglutination-inhibition antibodies against a panel of H3N2 influenza antigenic variants'

Terianne M. Wong¹, Anne-Gaelle Bebin-Blackwell¹, James D. Allen¹, Donald M. Carter¹, Timothy Alefantis², Joshua DiNapoli², Harold Kleanthous² and Ted M. Ross¹
(¹ *University of Georgia, Athens, Georgia, USA*; ² *Sanofi-Pasteur, Inc., Discovery Research, Cambridge, Massachusetts, USA*)

'Emergence and spread of antigenic variants for H3N2 influenza A viruses: Uncertainty and rapidity'

Xiu-Feng Wan, Lei Han, Lei Li and Tong Zhang

(*College of Veterinary Medicine, Mississippi State University, Mississippi, USA*)

'A novel amphibian innate immune mediator is virucidal for human influenza viruses'

Joshy Jacob (*Emory University, Atlanta, Georgia, USA*)

Tea Break & Posters

SESSION 4: INFLUENZA VACCINES

Moderator: Jonathan Van Tam (*University of Nottingham, Nottingham, UK*)

'The rationale for quadrivalent influenza vaccines'

Dirk Poelert (*GlaxoSmithKline, Wavre, Belgium*)

'A role for DNA immunization in preventing influenza infection'

Grant Weaver, Shixia Wang, and Shan Lu
(*University of Massachusetts Medical School, Worcester, Massachusetts, USA*)

'Broadly protective H5 influenza vaccine: Bettering the standard of care'

Harry Kleanthous¹, Timothy Alefantis¹, Josh Dinapoli¹, Stephen Anderson, Thorsten Vogel, Corey J. Crevar², Donald M. Carter², Ray Oomen, Mark Parrington¹, Nicholas Jackson and Ted M. Ross²
(¹ *Sanofi-Pasteur, Inc., Research, Cambridge, Massachusetts, USA*; ² *University of Georgia, Athens, Georgia, USA*)

'Pan-influenza A protection from group 1 and 2 viruses provided by X-31 cold-adapted live attenuated influenza vaccine'

Yo Han Jang¹, Joo Young Kim², Young Ho Byun¹, Ahyun Son¹, Yoon Jae Lee¹, Jun Chang² and Baik Lin Seong^{1,3}

(¹ *Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea*; ² *Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, South Korea*; ³ *Vaccine Translational Research Center, Yonsei University, Seoul, South Korea*)

'The effect of age and pre-existing immunity on seroconversion and backboosting in humans vaccinated with FluZone® in five consecutive influenza seasons'

Ted M. Ross¹, Ivette Nuñez¹, James D. Allen¹, Michael Carlock¹, Simon Owino¹, Simon Delagrave² and Harold Kleanthous²

(¹ *University of Georgia, Athens, Georgia, USA*; ² *Sanofi-Pasteur, Inc., Discovery Research, Cambridge, Massachusetts, USA*)

'A novel influenza vaccine targeting an epitope of limited variability'

Craig P. Thompson^{1,2}, José Lourenço¹, Mathew Edmans^{1,2}, Kreepa Kooblal³, Duncan Palmer¹, George Carnell⁴, Daniel O'Connor⁵, Thomas Bowden⁶, Andrew Pollard⁶, Nigel J. Temperton⁴, Teresa Lambe², Sarah Gilbert² and Sunetra Gupta¹

(¹ *Department of Zoology, University of Oxford, UK*; ² *The Jenner Institute Laboratories, University of Oxford, UK*; ³ *Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK*; ⁴ *Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, UK*; ⁵ *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK*; ⁶ *Division of Structural Biology, University of Oxford, UK*)

'A "magic" sequence to increase immunogenicity of recombinant prokaryotic and eukaryotic antigens'

I. Peubez¹, S. Margot¹, S. Buffin¹, H. Boukheba¹, A. Pilloud¹, C. Pion¹, V. Courtois¹, L. Potdevin¹, S. Commandeur¹, V. Marin¹, M.C. Bernard¹, P. Dinadayala¹, D. Poncet¹, R. Sodayer^{1,2}, J. Haensler¹ and I. Legastelois¹
(¹ *Research and Development, Sanofi Pasteur, Marcy L'toile, France*; ² *OITEI, Lyon, France*)

IVW 2017 Welcome Drinks Reception & Posters

**SESSION 5:
SPECIAL SESSION**

'Innate and acquired immunity to plant-made influenza VLP vaccines in adults and elderly'

Moderator: Nathalie Charland (*Medicago Inc., Quebec, Canada*)

Speakers to be confirmed

Sponsored by MEDICAGO



Coffee Break & Posters

**SESSION 6:
DELIVERY ROUTES**

Moderator: Manmohan Singh

(*Takeda Vaccines, Inc., Cambridge, Massachusetts, USA*)

'Clinical development of an inactivated nasal influenza vaccine'

Anna-Karin Maltais (*Eurocine Vaccines AB, Solna, Sweden*)

'Phase 1 trial of flu vaccination in the skin using a microneedle patch'

Nadine Roupheal (*Emory University, Atlanta, Georgia, USA*)

'Jet delivery of DNA: targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza'

Petra Mooij¹, Gunnveig Grødeland², Gerrit Koopman¹, Daniella Mortier¹, Ivonne G. Nieuwenhuis¹, Ernst Verschoor¹, Zahra Fagrouch¹, Willy M. Bogers¹ and Bjarne Bogen^{2,3}

(¹ *Biomedical Primate Research Centre, Rijswijk, The Netherlands*; ² *K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway*; ³ *Centre for Immune Regulation (CIR), Institute of Immunology, University of Oslo and Oslo University Hospital, Norway*)

'Intranasal immunization with influenza VLPs containing GPI-anchored CCL28 induces strong immune responses conferring heterologous protection'

Baozhong Wang (*Georgia State University, Atlanta, Georgia, USA*)

'The cross-protective potential and the protection-relevant immune mechanisms of whole inactivated virus vaccines are determined by adjuvants and route of immunization'

Yoshita Bhide¹, Wei Dong¹, Inta Gribonika³, Daniëlle Voshart¹, Tjarko Meijerhof¹, Jacqueline de Vries-Idema¹, Dennis Christensen², Nils Lycke³, Stephen Norley⁴, Diane Major⁵, Sarah Skeldon⁵, Othmar Engelhardt⁵ and Anke Huckriede¹
(¹ *University Medical Center Groningen, University of Groningen, Groningen, The Netherlands*; ² *Statens Serum Institut, Copenhagen, Denmark*; ³ *Gothenburg University, Gothenburg, Sweden*; ⁴ *Robert Koch Institute, Berlin, Germany*; ⁵ *National Institute for Biological Standards and Control (NIBSC), MHRA, Potters Bar, UK*)

'Challenges in influenza virus-like particles production: new analytical tools and downstream process optimization'

S.B. Carvalho^{1,2}, J.M. Freire³, R. Silva¹, M.G. Moleirinho¹, B. Cunha^{1,2}, A.S. Moreira¹, F. Monteiro^{1,2}, D. Gaspar³, M.A.R.B. Castanho³, G.J.L. Bernardes^{3,4}, D. Wheatley⁵, J. Welsh⁵, R. Gantier⁶, A. Xenopoulos⁷, P. M. Alves^{1,2}, C. Peixoto^{1,2} and M.J.T. Carrondo^{1,2,8}

(¹ *iBET, Oeiras, Portugal*; ² *ITQB-NOVA, Oeiras, Portugal*; ³ *Instituto de Medicina Molecular, Lisboa, Portugal*; ⁴ *University of Cambridge, Cambridge, UK*; ⁵ *Pall Life Sciences, UK*; ⁶ *Pall Life Sciences, USA*; ⁷ *EMD Millipore, USA*; ⁸ *FCT/UNL, Caparica, Portugal*)

Lunch Break & Posters

**SESSION 7:
UNIVERSAL INFLUENZA VACCINES – I**

Moderator: Sean Tucker (*VAXART Inc., South San Francisco, California, USA*)

'Improved influenza vaccines: What do we want?'

Justin Ortiz (*WHO, Geneva, Switzerland*)

'Progress in clinical development of novel influenza vaccines'

Sarah Gilbert (*University of Oxford, Oxford, UK*)

'Potency of H1 mini-HA universal influenza vaccine in the pre-exposed setting'

Harmjan Kuipers and Joan van der Lubbe
(*Janssen Vaccines and Prevention, Leiden, The Netherlands*)

'Large variation in effects of influenza vaccines pre- and post-2009 influenza H1N1 pandemic among community-dwelling older persons'

E. Hak (*University Groningen, Groningen, The Netherlands*)

Tea Break & Posters

**SESSION 8:
IVW 2017 WORKSHOP**

'Alternative potency assay development for influenza vaccines'

Moderators: Jon C. Bundy¹, Carrie L. Pierce¹ and Othmar G. Engelhardt²
(¹ *National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, GA USA*; ² *National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire, UK*)

'Opening Remarks'

Othmar Engelhardt (*National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire, UK*)

'Historical and current background on potency assays for vaccines'

Jerry Weir (*Center for Biologics Evaluation and Research, Food and Drug Administration (CBER/FDA) Baltimore, Maryland, USA*)

'Basis for measurement in novel influenza potency assays'

Ethan Septembre (*Sequiris, Cambridge, Massachusetts, USA*)

'Analytical challenges for developing alternative potency assays'

Terry Cyr (*Health Canada, Ottawa, Ontario Canada*)

'Use of mass spectrometry based standards for improving the influenza vaccine development pipeline'

Carrie Pierce (*National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA*)

'IFPMA/BARDA support in development of alternative potency assays'

To Be Confirmed

'Status of current approaches for novel alternative potency assays'

Jon Bundy (*National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA*)

'Progress of IFPMA/BARDA phase II potency assay comparison study'

To Be Confirmed – NIBSC Speaker

General Discussion

Closing Remarks

SESSION 9: UNIVERSAL INFLUENZA VACCINES – II

Moderator: Sarah Gilbert (*University of Oxford, Oxford, UK*)

'What is needed for the ultimate influenza vaccine?'

Rob Lambkin-Williams (*hVIVO Ltd, London, UK*)

'Universal influenza vaccine based on conserved antigen: Proof of concept studies'

Ze Chen (*Shanghai Institute of Biological Products Co., Ltd., Shanghai, China*)

'Recombinant adenovirus expressing influenza HA can effectively prime for heterologous neutralizing antibody responses'

Sean Tucker (*VAXART Inc., South San Francisco, California, USA*)

'Results of a Phase 1a study of M2SR influenza vaccine in healthy adults'

Pamuk Bilsel (*FluGen Inc., Madison, Wisconsin, USA*)

'Human quarantine experiments contribute to the science of universal influenza vaccines'

John Oxford (*Queen Mary College, University of London, London, UK*)

'Safety and immunogenicity of a BiondVax-developed universal influenza vaccine (Multimeric-001) followed by an administration of a H5N1 influenza vaccine'

Tamar Ben-Yedidia¹, Eva van Doorn², Atiqul Islam², Shimon Hassin², Ildiko Visontaj³, Stephan Norley⁴, Anke Huckriede⁵, Henderik W. Frijlink⁶ and Eelko Hak²

(¹ BiondVax Pharmaceuticals Ltd., Ness Ziona, Israel; ² University of Groningen, Groningen, The Netherlands; ³ National Center for Epidemiology, Budapest, Hungary; ⁴ Robert Koch Institute, Berlin, Germany; ⁵ University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ⁶ Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands)

Coffee Break & Posters

SESSION 10: FORMULATION, VACCINATION & REACTOGENICITY

Moderator: Rob Lambkin-Williams (*hVIVO Ltd, London, UK*)

'Rational vaccine formulation development using QbD Principles'

Manmohan Singh (*Takeda Vaccines, Inc., Cambridge, Massachusetts, USA*)

'Vaccinating in the presence of pre-existing immune responses'

Donald M. Carter¹, Christopher A. Darby¹, Timothy Alefantis², Joshua DiNapoli², Harold Kleanthous² and Ted M. Ross¹

(¹ University of Georgia, Athens, Georgia, USA; ² Sanofi-Pasteur, Inc., Discovery Research, Cambridge, Massachusetts, USA)

'Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge'

Christopher Karch¹, Jianping Li², Caroline Kulangara³, Sara M. Paulillo³, Senthil K. Raman³, Sharareh Emadi⁴, Anmin Tan⁴, Zeinab H. Helal^{2,5}, Qing Fan^{2,6}, Mazhar I. Khan² and Peter Burkhard³

(¹ University of Connecticut, Storrs, Connecticut, USA; ² Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, Connecticut, USA; ³ Alpha-O Peptides AG, Riehen, Switzerland; ⁴ Institute of Materials Science, University of Connecticut, Storrs, Connecticut, USA; ⁵ Department of Microbiology and Immunology, Faculty of Pharmacy, Alazhar-University, Cairo, Egypt; ⁶ Department of Biotechnology, Guangxi Veterinary Research Institute, Nanning, Guangxi, China)

'Rapid assessment of the reactivity of a 2016-2017 seasonal influenza vaccine: Results from a feasibility study'

Anke L. Stuurman¹, Thomas Verstraeten¹ and Antoon De Schryver²

(¹ P95 Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium; ² IDEWE, Leuven, Belgium)

'Infection-permissive immunity against influenza virus provided by vaccination prevents loss of alveolar macrophages and modulates virus-induced cross-reactive cellular immune responses during subsequent influenza infections'

Angela Choi¹, Joselin Andrea Morales Mina¹, Jan Spitaels^{2,3}, Adolfo Garcia-Sastre^{1,3} and Michael Schotsaert¹

(¹ Icahn School of Medicine at Mount Sinai, New York, New York, USA; ² Ghent University Department of Biomedical Molecular Biology, Ghent, Belgium; ³ Global Health and Emerging Pathogens Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai New York, New York, USA)

'Impact of prior influenza exposures on H3N2 cross-reactivity of human post-vaccination sera'

Hang Xie¹, Lei Li², Zhiping Ye¹, Xing Li¹, Ewan P. Plant¹, Olga Zoueva¹, Yangqing Zhao¹, Xianghong Jing¹, Zhengshi Lin¹, Toshiaki Kawano¹, Meng-Jung Chiang¹, Courtney Finch¹, Martina Kosikova¹, Anding Zhang¹, Yanhong Zhu¹ and Xiu-Feng Wan²

(¹ Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), Silver Spring, Maryland, USA; ² Mississippi State University, Mississippi, USA)

Lunch Break & Posters

SESSION 11: EVALUATION, EFFICACY & SAFETY

Moderator: Dirk Poelert (*GlaxoSmithKline, Wavre, Belgium*)

'Non-clinical investigations into the reduced effectiveness of the H1N1pdm09 component of the live attenuated influenza vaccine'

Helen Bright (*MedImmune Ltd, Liverpool, Merseyside, UK*)

'How do we evaluate the next generation of influenza vaccines: Beyond the HAI assay?'

Nicolas Noulin (*hVIVO Ltd, London, UK*)

'The EpiCC program: A new way of measuring influenza vaccine efficacy'

Oreda Boussadia (*EpiVax Inc., Lyon, France*)

'Observational study comparing safety of Flublok with a traditional egg-derived inactivated influenza vaccine'

Manon Cox (*Protein Sciences Corporation, Meriden, Connecticut, USA*)

'Improving the safety of a whole influenza virus vaccine through delipidation'

Motuharu Abe, Kazuyuki Ikeda, Ryo Yamaue, Issei Asano, Hiroto Onuma, Yusuke Ohyama, Kenta Matsuura, Hiroaki Mori, Kazuhiko Kimachi and Yoichiro Kino (*Kaketsuken, Kumamoto, Japan*)

'Assays for influenza vaccine immunogenicity evaluation and correlates of protection'

Emanuele Montomoli (*VisMederi Srl, Siena, Italy/University of Siena, Siena, Italy*)

Tea Break & Poster Breakdown

SESSION 12: CLOSING PLENARY

Moderator: John Oxford (*Queen Mary College, University of London, London, UK*)

CLOSING PLENARY PRESENTATIONS & DEBATE

'Influenza prevention: Vaccination uptake stagnation – a global public health failure?'

Bram Palache (*Independent Consultant, IFPMA, International Federation of Pharmaceutical Manufacturers & Associations, Geneva, Switzerland*)

'Public Health issues around switching from seasonal to pandemic vaccine production'

Gary Grohmann (*WHO, Geneva, Switzerland*)

'Statins, influenza vaccination and influenza'

David Fedson (*Independent Consultant, Sergy Haut, France*)

'Influenza Vaccines – The Continuing Challenge'

Ab Osterhaus (*University of Veterinary Medicine Hannover, Hannover, Germany*)

Debate: 'The Utility of the Challenge Model'

Debaters: Ab Osterhaus (*University of Veterinary Medicine Hannover, Hannover, Germany*) and Rob Lambkin-Williams (*hVIVO Ltd, London, UK*)

'How do we evaluate novel vaccines with unknown correlates of protection. What do we mean by vaccine efficacy. How, when most years seasonal vaccines are matched and have an efficacy of 50-70%, do you show a benefit for a mismatched strain. What is the role of ex-vivo models?'

Conference Close & Departure

* This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

REGISTRATION

Delegates should register for IVW 2017 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the IVW 2017 Conference Manager – Caroline Sumner at Meetings Management. The IVW 2017 Conference Registration Desk will be open from 8.00am on Wednesday 19th April 2017.

Delegates can also register securely on-line at:

www.meetingsmanagement.com/ivw_2017

VENUE & ACCOMMODATION

IVW 2017 will be held at:

CHUV, Lausanne, Switzerland

Accommodation: there are numerous hotels in Lausanne to suit most budgets. For information details on accommodation in Lausanne and other useful information, please visit:

<http://www.lausanne-tourisme.ch/en/>

Please note that the IVW 2017 conference organizers will not be recommending any specific hotels in Lausanne.

April is a busy time in Lausanne and it is recommended that IVW 2017 delegates book their accommodation without delay.

PUBLICATION

A USB storage device containing the final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £4995. If you do not wish to attend the conference sessions, you can reserve a table for £5995 (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Table Top Exhibition facilities at IVW 2017 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the IVW 2017 delegate pack is priced at £745. Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at IVW 2017 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: Literature for distribution to IVW 2017 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at IVW 2017. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The IVW 2017 Scientific Advisory Panel and the IVW 2017 Conference Organizers reserve the right to alter any part of the published provisional conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The provisional programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization's library up to date. The cost of providing this non-attendee package is £595 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner, IVW 2017 Conference Manager:

IVW 2017 Conference Secretariat, Meetings Management

The Old Dairy Tower, Peper Harow Park, Godalming
Surrey, GU8 6BD, United Kingdom.

Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

E-mail: csumner@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 31st March 2017. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 31st March 2017.

